Technology ID

Role of Novel Hepatitis Delta Virus Variant in Sjogren’s Syndrome

Lead Inventor
Chiorini, John (Jay) (NIDCR)
Weller, Melodie (NIDCR)
Research Materials
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Development Status
  • Early-stage
  • In vitro data available
  • In vivo data available (animal)
Research Products
Research Equipment
Sjögren’s is a chronic autoimmune disease characterized by dry mouth and eyes, fatigue, and musculoskeletal pain resulting from the attack of the moisture-producing glands by the body’s own white blood cells. The subject invention is based on the discovery of an association between infection by a novel clade 1 variant of hepatitis delta virus (HDV) and primary Sjögren’s syndrome. The association was made after detection of the HDV nucleic acid in the salivary glands of patients diagnosed with Sjögren’s syndrome and in vivo studies in mice that developed Sjögren’s syndrome-like pathogenesis after expression of HDV antigen. The discovery of this link opens the possibilities for developing diagnostics against HDV to determine who are at risk for developing Sjögren’s syndrome. The novel HDV variant can also serve as a potential therapeutic target for preventing or treating Sjögren’s.
Commercial Applications
  • Diagnostic for novel HDV clade 1 variant as a risk factor for developing Sjögren’s
  • Therapeutics against this newly discovered HDV clade 1 variant for prevention and/or treatment of Sjögren’s syndrome
Competitive Advantages
  • Novel diagnostic for a potentially significant risk factor in developing Sjögren’s syndrome
  • Newly discovered potential targets for treatment of Sjögren’s
Licensing Contact:
Knezevic, Vladimir
Phone: (240) 856-0274